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EFFICACY AND SAFETY OF EVEROLIMUS-EXEMESTANE COMBINATION IN
BREAST CANCER PATIENTS
Abstract
Breast cancer is the second leading cause of cancer death in women worldwide. In Lebanon, hormone
positive patients resistant to endocrine treatments account for most of the cases. These two facts directed
the attention to evaluate everolimus-exemestane use in hormonal receptor positive metastatic breast
cancer patients, in Lebanon. A multi-center, observational, retrospective cohort study was carried out by
screening 69 metastatic breast cancer patient’s files in order to determine the progression free survival
(PFS), overall survival (OS) and side effects of everolimus. This study revealed that across different therapy
lines, the median PFS for patients on everolimus-exemestane combination was 5.87 ± 10.84 months at
a median follow up of 5.135 ± 6.375, and the median survival was 23.83 months with minimum and
maximum survival, at 0.26 months and 30.5 months, respectively. Everolimus-exemestane has been shown
to be effective in overcoming hormonal resistance in Lebanese breast cancer patients. Stomatitis, as a
side effect of everolimus, accounted for 30.84% of the cases. Medical intervention, dose modification, dose
postponing, drug discontinuation, and spontaneous resolution were used to manage all side effects. In
comparison to previous studies, the current work demonstrated lower stomatitis percentages reflecting
the preventives measures taken by oncologists. As a conclusion, everolimus-exemestane coadministration has proven to be an effective combination in overcoming hormonal resistance in Lebanon
and a better tolerance is attributed to preventive measures in order to control drugs side effects.

Keywords
Breast cancer, Everolimus, Progression free survival, Overall survival, Metastasis

This article is available in BAU Journal - Health and Wellbeing: https://digitalcommons.bau.edu.lb/hwbjournal/vol1/
iss2/9

Jneid et al.: EFFICACY AND SAFETY OF EVEROLIMUS-EXEMESTANE COMBINATION IN BREAS

EFFICACY AND SAFETY OF EVEROLIMUS-EXEMESTANE
COMBINATION IN BREAST CANCER PATIENTS
S. JNEID1, S. HLAIS2, G. CHAHINE3, D. ISSA4, and S. DOMIATI5
Siba Jneid, Pharmacist at mutual fonctionel d’ etat
Department of Family Medicine, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
3
George Chahine, Department of Hematology, Faculty of Medicine, Saint Joseph University, Lebanon,
4
Doua Issa, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Beirut Arab University, Lebanon
5
Thouraya Domyati, Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Beirut Arab
University, Lebanon
1

2

ABSTRACT: Breast cancer is the second leading cause of cancer death in women worldwide. In
Lebanon, hormone positive patients resistant to endocrine treatments account for most of the cases.
These two facts directed the attention to evaluate everolimus-exemestane use in hormonal receptor
positive metastatic breast cancer patients, in Lebanon. A multi-center, observational, retrospective
cohort study was carried out by screening 69 metastatic breast cancer patient’s files in order to
determine the progression free survival (PFS), overall survival (OS) and side effects of everolimus.
This study revealed that across different therapy lines, the median PFS for patients on everolimusexemestane combination was 5.87 ± 10.84 months at a median follow up of 5.135 ± 6.375, and the
median survival was 23.83 months with minimum and maximum survival, at 0.26 months and 30.5
months, respectively. Everolimus-exemestane has been shown to be effective in overcoming
hormonal resistance in Lebanese breast cancer patients. Stomatitis, as a side effect of everolimus,
accounted for 30.84% of the cases. Medical intervention, dose modification, dose postponing, drug
discontinuation, and spontaneous resolution were used to manage all side effects. In comparison to
previous studies, the current work demonstrated lower stomatitis percentages reflecting the
preventives measures taken by oncologists. As a conclusion, everolimus-exemestane coadministration has proven to be an effective combination in overcoming hormonal resistance in
Lebanon and a better tolerance is attributed to preventive measures in order to control drugs side
effects.
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1.

INTRODUCTION
Breast cancer is the most common type of cancer (1) and the second leading cause of cancer mortality in women
worldwide (2). According to the International Agency for Research on Cancer (IARC), the worldwide incidence
of all types of cancer was estimated at 14.1 million in 2012, and the global burden was projected to grow to 21.7
million new cancer cases by 2030 (3).
Five main intrinsic subtypes of breast tumors are identified and classified according to the genes expressed,
namely: luminal A, luminal B, triple-negative/basal-like, human epidermal growth factor receptor type 2-enriched
(HER2), and normal-like. Seventy-five percent of breast cancer patients are estrogen receptor positive (4).
Endocrine therapy is the preferred option for hormone receptor positive disease, even in the presence of visceral
disease, unless there is a concern or proof of endocrine resistance or a rapidly progressing disease (3). In advanced
hormone positive breast cancer, up to 70% of cases develop a mutation in PI3K/Akt/mTOR pathway, and
hyperactivation of this pathway can lead to endocrine resistance (5). Metastatic patients are treated either with
hormonal therapy (endocrine therapy), targeted therapy, chemotherapy or a combination of these, depending on
breast cancer type.
Everolimus is a macrolide immunosuppressant and a first generation mammalian target of rapamycin inhibitor.
In 2009, everolimus was shown to significantly increase letrozole efficacy in neoadjuvant therapy for patients with
estrogen receptor positive breast cancer (6).
In 2012, everolimus was FDA approved for the treatment of advanced hormone receptor positive, and HER2negative breast cancer, in combination with exemestane (7). Furthermore, everolimus was also approved as first
line setting, in combination with exemestane, during or within 12 months following adjuvant treatment of
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metastatic stage after progression (8); other studies as well were recently conducted in a metastatic setting.
Additionally, everolimus was studied in HER-2 positive breast cancer (9), and current studies were conducted in
HER-2 positive breast cancer as well as in triple negative breast cancer.
Several side effects were indicated in everolimus treated patients, predominantly gastrointestinal disorders such
as stomatitis. Other frequently encountered side effects were endocrine and metabolic disorders, mostly
hyperglycemia and hyperlipidemia, respiratory side effects, mostly non-infectious pneumonitis, dermatologic,
hematologic, hepatic, renal, central nervous system, neuromuscular and skeletal disorders, and infections (10).
A Lebanese study, evaluating the efficacy of everolimus-exemestane co-therapy in reversing hormone resistance
in Lebanese breast cancer patients, showed a progression free survival (PFS) of 5.2 months (11). This value is
lower than 6.9 months, the value shown in BOLERO-2 trial that appraised the progression-free survival of
everolimus combined with an aromatase inhibitor in patients with hormone-receptor–positive advanced breast
cancer previously treated with non-steroidal aromatase inhibitors (8). Consequently, the current study was
conducted to assess the response, progression free survival and overall survival of everolimus-exemestane
combination and side effects of everolimus.
2.

METHODS
2.1 Study Design
This is a retrospective, observational, multi-center, cohort study conducted in Lebanon, and based on data
collected from five oncology clinics, geographically distributed over different areas in Lebanon from May 2015
through August 2015.
2.2 Inclusion and Exclusion Criteria
All Lebanese female adult patients, presenting to oncology clinics with histologically and pathologically
confirmed hormone receptor positive metastatic breast cancer were included in the study and treated with a
combination of everolimus (10 mg) and exemestane (25mg) daily. The exclusion criteria comprised patient
diagnosed with cancer other than breast cancer and male patient.
2.3 Data Collection
Patients’ medical profiles were reviewed and a survey form was filled. Socio-demographics, risk factors, family
history, medical history, prognosis, treatment, compliance to treatment, reasons for non-compliance, side effects
were retrieved. Progression free survival defined as time from initiation of index therapy to disease progression
or death was calculated. Overall survival defined as the time from initiation of index of therapy to death from any
cause was also documented. Patients without recorded death were censored at last follow-up date.
2.4 Ethical Consideration
Prior to data collection, verbal consent was taken from treating physicians in all oncology clinics included in the
study. Patients were referred to by their identification number for confidentiality purposes.
2.5 Statistical Analysis
Data was statistically analyzed using SPSS version 20 program, and median +/- SD (interquartile range) were
calculated for continuous data, while frequencies and percentages were calculated for nominal data.
Kaplan-Meier (K-M) analyses were used for comparison of progression free survival (PFS) between everolimusbased therapy in first, second, third, and fourth line and later lines metastatic stage; and also for overall survival
estimation after everolimus-based therapy in first, second, third, fourth line, and in all other lines use. Log rank
test was used to assess significance. Results were considered significant at p-value < 0.05.

3.

RESULTS
Data on 69 female patients with hormone positive metastatic breast cancer were collected from five oncology
clinics in different regions. At diagnosis of breast cancer, the mean age of participants was 52.54 ± 11.44 years,
and postmenopausal females constituted 50.73%. The median age of everolimus-exemestane combination
initiation was 60.36% ± 10.56 years. Twenty-five percent had family history of breast cancer. Forty eight point
seventy seven percent of the cases were either overweight or obese. Moreover, 19.04% of the patients had
hypertension, 14.28% had hyperlipidemia, 9.52% had diabetes and 9.52% had thyroid problems. Stage IIIC and
metastatic stage constituted 52.39% of cases at diagnosis (Table 1).
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Table 1: Demographic information of the studied sample
Age at Diagnosis (Mean ± SD)
Starting everolimus age (Median ± IQR)

52.54±11.44
60.36±10.56
Frequency (percentage)

Menopausal state at diagnosis of breast cancer
Premenopausal
Postmenopausal

34 (49.27%)
35 (50.73%)

Mount Lebanon
Beirut
North
South
Bekaa

28 (47.45%)
14 (23.72%)
11 (18.64%)
4 (6.77%)
2 (3.38%)

First Degree
Second degree
First and second degree
No Family history

1 (3.57%)
4 (14.28%)
2 (7.14%)
21 (75%)

Smoker
Non-smoker
Ex-smoker

10 (21.27%)
34 (72.34%)
3 (6.38%)

No comorbidities
Hypertension
Hyperlipidemia
Thyroid disorders
Diabetes mellitus
Cardiovascular disease
Kidney disease
Metabolic
Other

22 (34.92%)
12 (19.04%)
9 (14.28%)
6 (9.52%)
6 (9.52%)
3 (4.76%)
3 (4.76%)
1 (1.58%)
1 (1.58%)

Underweight
Normal
Overweight
Obese

1 (2.43%)
20 (48.78%)
15 (36.58%)
5 (12.19%)

Region of residency

Family History of Breast cancer

Smoking

Co-morbidities

Body Mass Index

In this study, the major site of metastasis before everolimus-exemestane combination administration was bones
(46%) followed by visceral metastasis including both liver and lungs (58%). The last medication preceding
everolimus-exemestane combination use in first and second lines were for non-steroidal aromatase inhibitors in a
percentage of 72.7% and 80%, respectively. On the other hand, this study showed increased chemotherapy use
preceding everolimus-exemestane combination in second (13.3%), third (15%), fourth (75%) and fifth (100%)
everolimus line therapies (Fig. 1).
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40%

75.0%
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30%

50.0%

20%

18.2%

6.7%

10%

9.1%

13.3%

first line
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chemotherapy
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fourth line

fulvestrant

fifth line

exemestane

sixth line

tamoxifen

seventh line

eigth line

letrozole/anastazole

Fig. 1 Last medication before starting everolimus-exemestane combination

Cum survival

Median progression free survival for everolimus-exemestane co-therapy was determined by the Kaplan-Meier
method at a median follow up of 5.135 ± 6.735 months. Across all therapy lines of everolimus-exemestane cotherapy, median PFS was 5.87 ± 10.84 months. In addition, median progression free survival for everolimusexemestane co-therapy in first, second, third, fourth and later line therapies were 4.94, 6.17 and 9.14, respectively
with no significant difference, log rank, or p-value=0.7418 (Fig. 2).

Months
Fig. 2 Kaplan-Meier curves of progression free survival after all lines of everolimus-exemestane co-therapy

Comparing first, second, third, fourth and later everolimus-exemestane line therapies, no significant difference
were found in median survival, p-value=0.5227. Median survival after everolimus in this research was 23.83
months with minimum and maximum survival, 0.26 months and 30.5 months, respectively (Fig. 3).
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Fig. 3 Kaplan-Meier curves of overall survival after all lines of everolimus-exemestane co-therapy

Cum survival

Lower median PFS was obtained in patients who were chemotherapy naïve (5.27 vs. 7 months) (Fig. 4), and
higher median PFS was noted in patients with non-bone metastasis (7 vs. 5.27 months) (Fig. 5).

Months
Fig. 4 Progression free survival of everolimus-exemestane combination regarding the last medication before starting everolimus
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Months
Fig. 5 Progression free survival of everolimus-exemestane combination according to the type of metastasis before everolimus use
(Bone vs. non-bone)

Several everolimus side effects were reported by patients most prominently stomatitis of any grade presenting
30.84% (Fig. 6).
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

Fig. 6 Side effects of everolimus encountered by the patients

During the course of the study, everolimus side effects were managed either by medical intervention in 45.2%
of cases, dose modification in 21.9%, dose postponing in 15.06%, drug discontinuation in 9.58%, or finally
spontaneous resolution in 8.21% (Fig. 7).
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8%
10%
45%
Medical Intervention

15%

Dose decreased
Dose postponed
Drug discontinuation
Spontaneous resolution

22%

Fig. 7 Side effects of everolimus management

A high percentage (77%) of patients in this research discontinued their treatment. Seventy-percent of patients
who discontinued everolimus did so due to progression, 17% due to side effects, 11.3% due to death and 1.88%
due to cost (Fig. 8).

70%

17%
11.30%
1.88%
Progression

Side effects

Death

Cost

Fig. 8 Reasons of everolimus discontinuation

4.

DISCUSSION
Family history of breast cancer is a major risk especially in females having one or more affected first-degree
relatives (3). This is reflected in the studied sample where 24.99% of the participants had one or more first or
second degree relatives or both with breast cancer. Age is another risk factor of breast cancer. In the current study,
the median age of everolimus-exemestane combination initiation (60.36% ± 10.56 years) was near the median age
reported by other studies (10). Considering obesity as an associated factor with increased risk of breast cancer,

Published by Digital Commons @ BAU, 2019

7

BAU Journal - Health and Wellbeing, Vol. 1, Iss. 2 [2019], Art. 9

48.77% of cases were either overweight or obese in this study (13). As such, regular exercise, weight loss and a
healthy diet are crucial in order to maintain an adequate BMI.
Stage IIIC and metastatic stage constituted 52.39% of cases at diagnosis. This finding imposes better awareness
among the Lebanese females in order to detect breast cancer in its early stages. Moreover, the bone was shown to
be the major site of metastasis (46.4%) followed by visceral metastasis including liver and lungs (58%) before
initiation of everolimus-exemestane combination comparably to cases in previous studies published by Baselda
et. al., Thaddeus et al. and others (7-8, 14-16).
Non-steroidal aromatase inhibitors accounted mostly as the last medication preceding everolimus-exemestane
co-therapy in the first and second lines similar to the results of BRAWO trial (14-16). This study showed increased
chemotherapy use preceding everolimus-exemestane combination as identified also by previous studies (14-16).
In fact, these matched results demonstrated a reflection of the level of common practice in Lebanon. Although
NCCN guidelines recommended consecutively using three lines of endocrine therapy before switching to
chemotherapy, some physicians in community-based oncology practices in Lebanon reserved everolimusexemestane combination till after chemotherapy failure.
Across all therapy lines of everolimus-exemestane co-therapy, median progression-free survival (PFS) was 5.87
± 10.84 months similar to Assi et al results which showed a median PFS of 5.2 months since the initiation of
therapy (11). On the other hand, the median PFS was different from other median PFS found by Baselda et. al.,
Thaddeus et al. and others (7-8, 14-17). In fact, results identified by previous studies showed higher values in first
and second line therapies and lower values in third and fourth line therapies (14-16). Furthermore, no specific
line of everolimus-based therapy was powered over another in terms of survival. Median survival, in this study,
was inferior to that of BOLERO-2 trial which showed a median survival of 31 months (18), but was within median
survival of individuals with metastatic breast cancer that varied between 18 and 24 months (19); and this might be
related to the exclusions done in ECOG 3 trial as well as in the BOLERO-2 trial, resulting in higher survival.
Contrasting the findings obtained by the study conducted by Assi et al (11), lower median PFS was obtained in
patients who were chemotherapy naïve (5.27 vs. 7 months). These results strengthen the susceptibility that
physicians in community-based oncology practices reserved everolimus until chemotherapy failure. In accordance
with the study conducted by Assi et al (11), higher median PFS was noted in patients with non-bone metastasis (7
vs. 5.27 months). As a result, everolimus-exemestane combination could be a good option for patients with
metastasis other than bone.
Stomatitis percentage in this study is lower than those cited in the literature (7, 14-16), and they were due to the
impact of prophylactic measures and careful monitoring during treatment. In fact, good side effects management
played a key role in reducing everolimus discontinuation. Nevertheless, the major reason for everolimus
discontinuation was progression followed by side effects as stated by the literature (7).
5.

CONCLUSIONS
Everolimus-exemestane co-therapy has proven to be an effective combination in overcoming hormonal
resistance in Lebanese breast cancer patients with results slightly inferior to those reported in the BOLERO-2
population. Good tolerance of the drug could be attributed to a control of the drug’s side effects via adapted and
preventive effective strategies. Further prospective study is needed to assure these findings.
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